ID: hyp-SDA-2026-04-08-gap-debate-20260406-0
Hypothesis
Lipid Droplet Dynamics as Therapeutic Lever
Target DGAT1/DGAT2 inhibition or ATGL activation to restore metabolic homeostasis by addressing lipid metabolism dysfunction unique to APOE4 carriers.
EvidencePending (0%)📖 5 cit🗣 1 debates✓ 5 support✗ 1 oppose
✓ All Quality Gates Passed
🧪 Overview
Target DGAT1/DGAT2 inhibition or ATGL activation to restore metabolic homeostasis by addressing lipid metabolism dysfunction unique to APOE4 carriers
🧬 Mechanism
🧬 Curated Mechanism Pathway
Curated pathway from expert analysis
flowchart TD
A["APOE4 Microglial Lipid Dyshomeostasis<br/>Excess Neutral Lipid Accumulation"]
B["DGAT1 DGAT2 Overactivation<br/>Diacylglycerol to Triglyceride Conversion"]
C["Lipid Droplet Overloading<br/>Organelle Function Impaired"]
D["ATGL Lipase Activity Reduced<br/>Impaired Triglyceride Lipolysis"]
E["DGAT1 DGAT2 Inhibitor Treatment<br/>A922500 DGAT1i or Prevents LD Formation"]
F["ATGL Activator Treatment<br/>Restores Lipid Droplet Turnover"]
G["Metabolic Homeostasis Restored<br/>Neutral Lipid Cleared"]
H["Microglial Phagocytic Function Recovered<br/>Amyloid Debris Clearance"]
A --> B
B --> C
D --> C
E -.->|"reduces LD formation"| C
F --> D
E --> G
F --> G
G --> H
style C fill:#7b1fa2,stroke:#ce93d8,color:#ce93d8
style H fill:#1b5e20,stroke:#a5d6a7,color:#a5d6a7⚖️ Evidence
⚖️ Evidence Matrix5 supports0 contradicts
📖 Linked Papers
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — DGAT1
No curated PDB or AlphaFold mapping for DGAT1 yet. Search RCSB →
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for DGAT1.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↔
Stable
7d Momentum
▲ 0.0%
Volatility
High
0.0527
Events (7d)
0
Price History
▲5.7%💾 Resource Usage
LLM Tokens
12,984
$0.0779
Total Cost
$0.0779
🔮 Predictions
🔎 Predictions vs Observations2 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF ATGL is genetically activated (ATGL overexpression or ATGL activator) in APOE4 knock-in mouse astrocytes THEN spatial memory and hippocampal CA1 neuronal metabolic function will improve, with reduc | Improvement in Morris water mazelatency to platform (≥25% reduction vs. APOE4 controls), 40% reduction in hippocampal C16:0 and C18:0 ceramide levels via LC-MS/ | — no observation — | pending | 0.68 |
| IF DGAT1 is pharmacologically inhibited (e.g., with DGAT1 inhibitor A922513 or DGAT1-targeted siRNA) in human iPSC-derived neurons from APOE4 carriers THEN intracellular lipid droplet accumulation wil | Significant reduction in lipid droplet number (≥40% decrease) and mean size (≥30% decrease) as quantified by Adipored staining and high-content imaging, with co | — no observation — | pending | 0.75 |
🔮 Falsifiable Predictions (2)
pendingconf 75%
IF DGAT1 is pharmacologically inhibited (e.g., with DGAT1 inhibitor A922513 or DGAT1-targeted siRNA) in human iPSC-derived neurons from APOE4 carriers THEN intracellular lipid droplet accumulation will decrease significantly compared to vehicle-treated controls within 72 hours using human iPSC-deriv
Predicted outcome: Significant reduction in lipid droplet number (≥40% decrease) and mean size (≥30% decrease) as quantified by Adipored staining and high-content imagin
Falsification: No significant change (p>0.05) or increase in lipid droplet accumulation despite verified DGAT1 inhibition, indicating lipid droplets in APOE4 neurons are not primarily DGAT1-dependent and the hypothe
pendingconf 68%
IF ATGL is genetically activated (ATGL overexpression or ATGL activator) in APOE4 knock-in mouse astrocytes THEN spatial memory and hippocampal CA1 neuronal metabolic function will improve, with reduced ceramides and increased mitochondrial respiration, within 4 weeks using APOE4/4 knock-in mouse mo
Predicted outcome: Improvement in Morris water mazelatency to platform (≥25% reduction vs. APOE4 controls), 40% reduction in hippocampal C16:0 and C18:0 ceramide levels
Falsification: No improvement in spatial memory performance, no reduction in toxic lipid species (ceramides/sphingomyelin), and no enhancement of mitochondrial respiration despite confirmed ATGL activation (ATGL pro
▸Metadatasource: v1_phase_c_backfill · origin_type: debate_synthesis
| source | v1_phase_c_backfill |
| origin_type | debate_synthesis |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.